Avdoralimab Uses, Dosage, Side Effects and more
Avdoralimab is under investigation in clinical trial NCT04333914 (Prospective Study in Patients With Advanced or Metastatic Cancer and Sars-cov-2 Infection).
Attribute | Details |
---|---|
Trade Name | Avdoralimab |
Generic | Avdoralimab |
Avdoralimab Other Names | Avdoralimab |
Type | |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | January 7, 2025 at 1:49 am |
How Avdoralimab works
Avdoralimab binds and inhibits C5a receptors (C5aR) expressed on myeloid-derived suppressor cells and neutrophils. C5a is often associated with tumors; by blocking the binding of C5a to C5aR, Advoralimab reduces the activation of MDSC and neutrophils in tumor microenvironments, thus exhibiting anti-tumor activity.